ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Orphan Indication Drugs Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-4R15525
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Orphan Indication Drugs Market Research Report 2023
BUY CHAPTERS

Global Orphan Indication Drugs Market Research Report 2025

Code: QYRE-Auto-4R15525
Report
January 2025
Pages:95
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bristol–Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer Inc
Amgen Inc
Sanofi
Astrazeneca plc
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly

Orphan Indication Drugs Market Size

The global market for Orphan Indication Drugs was valued at US$ 654 million in the year 2024 and is projected to reach a revised size of US$ 765 million by 2031, growing at a CAGR of 2.3% during the forecast period.

Orphan Indication Drugs Market

Orphan Indication Drugs Market

An orphan drug is a drug used to treat a disease that cannot be produced profitably without government assistance because of the small number of patients.The classification of certain diseases, and the medicines that treat them, as "orphan" is a matter of public policy in many countries . Given the nature of the enormous economic resources required for medical research , these medicines would have no chance of producing breakthroughs that otherwise might not have been possible without government assistance.In the United States and the European Union , orphan drugs are easier to obtain marketing authorization. There may also be additional financial incentives, such as an extension of the market exclusivity period, which would allow the pharmaceutical company to have a longer exclusivity to sell the drug. All of these measures are designed to encourage drug development, and without this kind of profit motive , few pharmaceutical companies will be willing to allocate their budgets and personnel to this type of research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Orphan Indication Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Orphan Indication Drugs.
The Orphan Indication Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Orphan Indication Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Orphan Indication Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Orphan Indication Drugs Market Report

Report Metric Details
Report Name Orphan Indication Drugs Market
Accounted market size in year US$ 654 million
Forecasted market size in 2031 US$ 765 million
CAGR 2.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Biologics
  • Non-Biologics
Segment by Application
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, Pfizer, Amgen, Sanofi, AstraZeneca, Takeda, Vertex Pharmaceuticals, AbbVie, Biogen, Eli Lilly
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Orphan Indication Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Orphan Indication Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Orphan Indication Drugs Market growing?

Ans: The Orphan Indication Drugs Market witnessing a CAGR of 2.3% during the forecast period 2025-2031.

What is the Orphan Indication Drugs Market size in 2031?

Ans: The Orphan Indication Drugs Market size in 2031 will be US$ 765 million.

Who are the main players in the Orphan Indication Drugs Market report?

Ans: The main players in the Orphan Indication Drugs Market are Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, Pfizer, Amgen, Sanofi, AstraZeneca, Takeda, Vertex Pharmaceuticals, AbbVie, Biogen, Eli Lilly

What are the Application segmentation covered in the Orphan Indication Drugs Market report?

Ans: The Applications covered in the Orphan Indication Drugs Market report are Hospital Pharmacy, Retail Pharmacy, Online Sales

What are the Type segmentation covered in the Orphan Indication Drugs Market report?

Ans: The Types covered in the Orphan Indication Drugs Market report are Biologics, Non-Biologics

Recommended Reports

Orphan Disease Drugs

Pharmaceutical Market Trends

Chronic & Rare Drug Treatment

1 Orphan Indication Drugs Market Overview
1.1 Product Definition
1.2 Orphan Indication Drugs by Type
1.2.1 Global Orphan Indication Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Biologics
1.2.3 Non-Biologics
1.3 Orphan Indication Drugs by Application
1.3.1 Global Orphan Indication Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Sales
1.4 Global Orphan Indication Drugs Market Size Estimates and Forecasts
1.4.1 Global Orphan Indication Drugs Revenue 2020-2031
1.4.2 Global Orphan Indication Drugs Sales 2020-2031
1.4.3 Global Orphan Indication Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Orphan Indication Drugs Market Competition by Manufacturers
2.1 Global Orphan Indication Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Orphan Indication Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Orphan Indication Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Orphan Indication Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Orphan Indication Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Orphan Indication Drugs, Product Type & Application
2.7 Global Key Manufacturers of Orphan Indication Drugs, Date of Enter into This Industry
2.8 Global Orphan Indication Drugs Market Competitive Situation and Trends
2.8.1 Global Orphan Indication Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Orphan Indication Drugs Players Market Share by Revenue
2.8.3 Global Orphan Indication Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Orphan Indication Drugs Market Scenario by Region
3.1 Global Orphan Indication Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Orphan Indication Drugs Sales by Region: 2020-2031
3.2.1 Global Orphan Indication Drugs Sales by Region: 2020-2025
3.2.2 Global Orphan Indication Drugs Sales by Region: 2026-2031
3.3 Global Orphan Indication Drugs Revenue by Region: 2020-2031
3.3.1 Global Orphan Indication Drugs Revenue by Region: 2020-2025
3.3.2 Global Orphan Indication Drugs Revenue by Region: 2026-2031
3.4 North America Orphan Indication Drugs Market Facts & Figures by Country
3.4.1 North America Orphan Indication Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Orphan Indication Drugs Sales by Country (2020-2031)
3.4.3 North America Orphan Indication Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Orphan Indication Drugs Market Facts & Figures by Country
3.5.1 Europe Orphan Indication Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Orphan Indication Drugs Sales by Country (2020-2031)
3.5.3 Europe Orphan Indication Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Orphan Indication Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Orphan Indication Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Orphan Indication Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Orphan Indication Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Orphan Indication Drugs Market Facts & Figures by Country
3.7.1 Latin America Orphan Indication Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Orphan Indication Drugs Sales by Country (2020-2031)
3.7.3 Latin America Orphan Indication Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Orphan Indication Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Orphan Indication Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Orphan Indication Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Orphan Indication Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Orphan Indication Drugs Sales by Type (2020-2031)
4.1.1 Global Orphan Indication Drugs Sales by Type (2020-2025)
4.1.2 Global Orphan Indication Drugs Sales by Type (2026-2031)
4.1.3 Global Orphan Indication Drugs Sales Market Share by Type (2020-2031)
4.2 Global Orphan Indication Drugs Revenue by Type (2020-2031)
4.2.1 Global Orphan Indication Drugs Revenue by Type (2020-2025)
4.2.2 Global Orphan Indication Drugs Revenue by Type (2026-2031)
4.2.3 Global Orphan Indication Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Orphan Indication Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Orphan Indication Drugs Sales by Application (2020-2031)
5.1.1 Global Orphan Indication Drugs Sales by Application (2020-2025)
5.1.2 Global Orphan Indication Drugs Sales by Application (2026-2031)
5.1.3 Global Orphan Indication Drugs Sales Market Share by Application (2020-2031)
5.2 Global Orphan Indication Drugs Revenue by Application (2020-2031)
5.2.1 Global Orphan Indication Drugs Revenue by Application (2020-2025)
5.2.2 Global Orphan Indication Drugs Revenue by Application (2026-2031)
5.2.3 Global Orphan Indication Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Orphan Indication Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Company Information
6.1.2 Bristol-Myers Squibb Description and Business Overview
6.1.3 Bristol-Myers Squibb Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bristol-Myers Squibb Orphan Indication Drugs Product Portfolio
6.1.5 Bristol-Myers Squibb Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Orphan Indication Drugs Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis Orphan Indication Drugs Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Company Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Johnson & Johnson Orphan Indication Drugs Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Orphan Indication Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Amgen
6.6.1 Amgen Company Information
6.6.2 Amgen Description and Business Overview
6.6.3 Amgen Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Amgen Orphan Indication Drugs Product Portfolio
6.6.5 Amgen Recent Developments/Updates
6.7 Sanofi
6.7.1 Sanofi Company Information
6.7.2 Sanofi Description and Business Overview
6.7.3 Sanofi Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Sanofi Orphan Indication Drugs Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Company Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 AstraZeneca Orphan Indication Drugs Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Takeda
6.9.1 Takeda Company Information
6.9.2 Takeda Description and Business Overview
6.9.3 Takeda Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Takeda Orphan Indication Drugs Product Portfolio
6.9.5 Takeda Recent Developments/Updates
6.10 Vertex Pharmaceuticals
6.10.1 Vertex Pharmaceuticals Company Information
6.10.2 Vertex Pharmaceuticals Description and Business Overview
6.10.3 Vertex Pharmaceuticals Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Vertex Pharmaceuticals Orphan Indication Drugs Product Portfolio
6.10.5 Vertex Pharmaceuticals Recent Developments/Updates
6.11 AbbVie
6.11.1 AbbVie Company Information
6.11.2 AbbVie Description and Business Overview
6.11.3 AbbVie Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 AbbVie Orphan Indication Drugs Product Portfolio
6.11.5 AbbVie Recent Developments/Updates
6.12 Biogen
6.12.1 Biogen Company Information
6.12.2 Biogen Description and Business Overview
6.12.3 Biogen Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Biogen Orphan Indication Drugs Product Portfolio
6.12.5 Biogen Recent Developments/Updates
6.13 Eli Lilly
6.13.1 Eli Lilly Company Information
6.13.2 Eli Lilly Description and Business Overview
6.13.3 Eli Lilly Orphan Indication Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Eli Lilly Orphan Indication Drugs Product Portfolio
6.13.5 Eli Lilly Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Orphan Indication Drugs Industry Chain Analysis
7.2 Orphan Indication Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Orphan Indication Drugs Production Mode & Process Analysis
7.4 Orphan Indication Drugs Sales and Marketing
7.4.1 Orphan Indication Drugs Sales Channels
7.4.2 Orphan Indication Drugs Distributors
7.5 Orphan Indication Drugs Customer Analysis
8 Orphan Indication Drugs Market Dynamics
8.1 Orphan Indication Drugs Industry Trends
8.2 Orphan Indication Drugs Market Drivers
8.3 Orphan Indication Drugs Market Challenges
8.4 Orphan Indication Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bristol–Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer Inc
Amgen Inc
Sanofi
Astrazeneca plc
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly
List of Tables
 Table 1. Global Orphan Indication Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Orphan Indication Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Orphan Indication Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Orphan Indication Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Orphan Indication Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Orphan Indication Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Orphan Indication Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Orphan Indication Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Orphan Indication Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Orphan Indication Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Orphan Indication Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Orphan Indication Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Orphan Indication Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Indication Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Orphan Indication Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Orphan Indication Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Orphan Indication Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Orphan Indication Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Orphan Indication Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Orphan Indication Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Orphan Indication Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Orphan Indication Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Orphan Indication Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Orphan Indication Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Orphan Indication Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Orphan Indication Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Orphan Indication Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Orphan Indication Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Orphan Indication Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Orphan Indication Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Orphan Indication Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Orphan Indication Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Orphan Indication Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Orphan Indication Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Orphan Indication Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Orphan Indication Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Orphan Indication Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Orphan Indication Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Orphan Indication Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Orphan Indication Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Orphan Indication Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Orphan Indication Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Orphan Indication Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Orphan Indication Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Orphan Indication Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Orphan Indication Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Orphan Indication Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Orphan Indication Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Orphan Indication Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Orphan Indication Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Orphan Indication Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Orphan Indication Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Orphan Indication Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Orphan Indication Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Orphan Indication Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Orphan Indication Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Orphan Indication Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Orphan Indication Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Orphan Indication Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Orphan Indication Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Orphan Indication Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Orphan Indication Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Orphan Indication Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Orphan Indication Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Orphan Indication Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Orphan Indication Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Orphan Indication Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Orphan Indication Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. Bristol-Myers Squibb Company Information
 Table 71. Bristol-Myers Squibb Description and Business Overview
 Table 72. Bristol-Myers Squibb Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Bristol-Myers Squibb Orphan Indication Drugs Product
 Table 74. Bristol-Myers Squibb Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Roche Orphan Indication Drugs Product
 Table 79. Roche Recent Developments/Updates
 Table 80. Novartis Company Information
 Table 81. Novartis Description and Business Overview
 Table 82. Novartis Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Novartis Orphan Indication Drugs Product
 Table 84. Novartis Recent Developments/Updates
 Table 85. Johnson & Johnson Company Information
 Table 86. Johnson & Johnson Description and Business Overview
 Table 87. Johnson & Johnson Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Johnson & Johnson Orphan Indication Drugs Product
 Table 89. Johnson & Johnson Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Orphan Indication Drugs Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. Amgen Company Information
 Table 96. Amgen Description and Business Overview
 Table 97. Amgen Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Amgen Orphan Indication Drugs Product
 Table 99. Amgen Recent Developments/Updates
 Table 100. Sanofi Company Information
 Table 101. Sanofi Description and Business Overview
 Table 102. Sanofi Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Sanofi Orphan Indication Drugs Product
 Table 104. Sanofi Recent Developments/Updates
 Table 105. AstraZeneca Company Information
 Table 106. AstraZeneca Description and Business Overview
 Table 107. AstraZeneca Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. AstraZeneca Orphan Indication Drugs Product
 Table 109. AstraZeneca Recent Developments/Updates
 Table 110. Takeda Company Information
 Table 111. Takeda Description and Business Overview
 Table 112. Takeda Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Takeda Orphan Indication Drugs Product
 Table 114. Takeda Recent Developments/Updates
 Table 115. Vertex Pharmaceuticals Company Information
 Table 116. Vertex Pharmaceuticals Description and Business Overview
 Table 117. Vertex Pharmaceuticals Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Vertex Pharmaceuticals Orphan Indication Drugs Product
 Table 119. Vertex Pharmaceuticals Recent Developments/Updates
 Table 120. AbbVie Company Information
 Table 121. AbbVie Description and Business Overview
 Table 122. AbbVie Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. AbbVie Orphan Indication Drugs Product
 Table 124. AbbVie Recent Developments/Updates
 Table 125. Biogen Company Information
 Table 126. Biogen Description and Business Overview
 Table 127. Biogen Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Biogen Orphan Indication Drugs Product
 Table 129. Biogen Recent Developments/Updates
 Table 130. Eli Lilly Company Information
 Table 131. Eli Lilly Description and Business Overview
 Table 132. Eli Lilly Orphan Indication Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Eli Lilly Orphan Indication Drugs Product
 Table 134. Eli Lilly Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Orphan Indication Drugs Distributors List
 Table 138. Orphan Indication Drugs Customers List
 Table 139. Orphan Indication Drugs Market Trends
 Table 140. Orphan Indication Drugs Market Drivers
 Table 141. Orphan Indication Drugs Market Challenges
 Table 142. Orphan Indication Drugs Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Orphan Indication Drugs
 Figure 2. Global Orphan Indication Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Orphan Indication Drugs Market Share by Type: 2024 & 2031
 Figure 4. Biologics Product Picture
 Figure 5. Non-Biologics Product Picture
 Figure 6. Global Orphan Indication Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Orphan Indication Drugs Market Share by Application: 2024 & 2031
 Figure 8. Hospital Pharmacy
 Figure 9. Retail Pharmacy
 Figure 10. Online Sales
 Figure 11. Global Orphan Indication Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Orphan Indication Drugs Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Orphan Indication Drugs Sales (2020-2031) & (K Units)
 Figure 14. Global Orphan Indication Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 15. Orphan Indication Drugs Report Years Considered
 Figure 16. Orphan Indication Drugs Sales Share by Manufacturers in 2024
 Figure 17. Global Orphan Indication Drugs Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Orphan Indication Drugs Players: Market Share by Revenue in Orphan Indication Drugs in 2024
 Figure 19. Orphan Indication Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Orphan Indication Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Orphan Indication Drugs Sales Market Share by Country (2020-2031)
 Figure 22. North America Orphan Indication Drugs Revenue Market Share by Country (2020-2031)
 Figure 23. United States Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Orphan Indication Drugs Sales Market Share by Country (2020-2031)
 Figure 26. Europe Orphan Indication Drugs Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Orphan Indication Drugs Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Orphan Indication Drugs Revenue Market Share by Region (2020-2031)
 Figure 34. China Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Orphan Indication Drugs Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Orphan Indication Drugs Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Orphan Indication Drugs Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Orphan Indication Drugs Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Orphan Indication Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Orphan Indication Drugs by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Orphan Indication Drugs by Type (2020-2031)
 Figure 55. Global Orphan Indication Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Orphan Indication Drugs by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Orphan Indication Drugs by Application (2020-2031)
 Figure 58. Global Orphan Indication Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 59. Orphan Indication Drugs Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Orphan Drugs for Adults Market Research Report 2025
Global Pediatric Orphan Drugs Market Research Report 2025
Global Pediatric Orphan Drug Market Research Report 2024
Orphan Lung Diseases Treatment Market
Rare Disease Clinical Trial Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Primary Immunodeficiency Drug Market Research Report 2025
Global Pediatric Medicines Market Research Report 2024
Global Patent Drug Market Research Report 2025
Global Innovation Drug Research and Development Platform Market Research Report 2024
Global Outsourcing in Drug Discovery Market Research Report 2024
Global High end Generic Drug Market Research Report 2024
Stem Cell Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Rare Disease Drug Market Research Report 2024
Global Albinism Drug Market Insights Forecast to 2030
Global Innovative Drug Market Insights Forecast to 2030
Outsourced Drug Discovery Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Branded Generics Market
Global Breast Cancer Targeted Drug Market Research Report 2025
Global Pediatric Drug Research and Development Platform Market Research Report 2024
Pharmaceutical Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions